Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favorite is the 49% year-over-year increase in Breyanzi sales to $392 million in Q4. Also, on January 20, BMS announced an important decision to deploy Microsoft's Precision Imaging Network with the ultimate goal of more accurately identifying patients with earlier stages of lung cancer. In this article, you will learn why despite some risks, Bristol-Myers Squibb is still one of the best choices among Big Pharma for long-term investors. PeopleImages/iStock via Getty Images Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time. And as This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Dr. Reddy's biosimilar for Bristol's Orencia undergoes FDA review [Seeking Alpha]Seeking Alpha
- Bristol Myers Squibb (NYSE:BMY) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Bristol-Myers: I'm Buying Post Earnings [Seeking Alpha]Seeking Alpha
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsightPR Newswire
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsightPR Newswire
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 2/11/26 - Form 10-K
- 2/5/26 - Form 8-K
- 2/3/26 - Form 4
- BMY's page on the SEC website